Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

New evidence supports continuous infusion for GI cancers

New research just published online by JNCCN-; Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens targeting metastatic gastrointestinal (GI) cancers, such as FOLFOX, FOLFIRI, or FOLFIRINOX, it is possible to administer 5-FU solely through continuous infusion, minus the bolus (quick-delivery via intravenous push) component, without negatively affecting patient outcomes.

6 Sep 2024

Rare but real: The neurological risks associated with vaccines

Review highlights the rare neurological risks associated with vaccination, emphasizing the importance of accurate detection and management strategies, particularly in the context of the COVID-19 pandemic.

9 Aug 2024

Investigational drug shows promise in treating rare blood disease in fetuses

Data from a new investigational drug that could alter the standard treatment for a rare blood disease suggests it has the potential to delay or prevent anemia and the need for intrauterine blood transfusions in babies who are at high risk for the condition, known as Hemolytic Disease of the Fetus and Newborn (HDFN).

7 Aug 2024

Study confirms cardiovascular safety of COVID-19 vaccines among millions of adults in England

A study confirms the cardiovascular safety of different COVID-19 vaccine doses, showing reduced risks of common cardiovascular events among vaccinated adults in England.

4 Aug 2024

COVID vaccines shown to reduce risk of arterial thrombosis

A new study, published today in Nature Communications and involving nearly the whole adult population of England, has found that the incidence of heart attacks and strokes was lower after COVID-19 vaccination than before or without vaccination.

1 Aug 2024

Study finds lower risk of heart attacks and strokes after COVID-19 vaccination

The incidence of heart attacks and strokes was lower after COVID-19 vaccination than before or without vaccination, according to a new study involving nearly the whole adult population of England.

31 Jul 2024

Cytomegalovirus in breast milk linked to changes in infant growth and gut microbiome

Research shows human cytomegalovirus (CMV) reactivation in breast milk affects milk composition, infant gut microbiome, and growth, with potential impacts on neonatal health.

28 Jul 2024

Unraveling the role of TAL1 and miR-146b-5p in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that arises from the malignant transformation of T-cell progenitors.

23 Jul 2024

DDX41: A unique player in myeloid leukemogenesis

A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, "DDX41 and its unique contribution to myeloid leukemogenesis."

19 Jul 2024

Unexpected T-cell reactions to adenoviral COVID-19 vaccines discovered

Researchers from the University of Liverpool's Centre for Drug Safety Science have identified unpredicted T-cell immune responses to the adenoviral (Oxford/AstraZeneca and Janssen) COVID-19 vaccines, but not to the mRNA vaccines.

19 Jul 2024

Understanding the platelet-monocyte interaction to improve treatment of immune disorders

Monocytes, a special type of white blood cell, secrete cytokines as inflammatory messengers that are crucial for an appropriate immune response.

8 Jul 2024

MEK inhibitor trametinib shows potential in pediatric JMML treatment

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years.

13 Jun 2024

Research expands understanding of vaccine-induced immune thrombocytopenia and thrombosis

New research led by Flinders University and international experts is expanding understanding of vaccine-induced immune thrombocytopenia and thrombosis (known as VITT).

16 May 2024

Acupuncture is beneficial in reducing the incidence of ischaemic stroke

The effectiveness of acupuncture in reducing the risk of ischemic stroke among patients with rheumatoid arthritis (RA).

14 Feb 2024

New scientific statement outlines recommendations for diagnosing, managing cerebral venous thrombosis

A new scientific statement from the American Heart Association emphasizes the need to increase patients' and physicians' awareness of cerebral venous thrombosis (CVT) to improve the recognition of this condition and initiate prompt medical treatment.

29 Jan 2024

Large UK study highlights gaps in COVID-19 vaccine coverage

The first research study of the entire UK population highlights gaps in COVID-19 vaccine coverage. Between a third and a half of the populations of the four UK nations had not had the recommended number of COVID vaccinations and boosters by summer 2022.

16 Jan 2024

Study shows slight increase in Guillain-Barre syndrome risk with adenovirus COVID vaccines

Study investigates the link between COVID-19 vaccines and autoimmune/neurological diseases, focusing on Guillain-Barre syndrome (GBS) risks associated with adenovirus vector vaccines.

16 Jan 2024

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.